188 related articles for article (PubMed ID: 22523304)
1. A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.
Li Y; Mick R; Heitjan DF
Clin Trials; 2012 Jun; 9(3):293-302. PubMed ID: 22523304
[TBL] [Abstract][Full Text] [Related]
2. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
4. A confidence function-based posterior probability design for phase II cancer trials.
Shan M
Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
[TBL] [Abstract][Full Text] [Related]
5. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
Sill MW; Rubinstein L; Litwin S; Yothers G
Clin Trials; 2012 Aug; 9(4):385-95. PubMed ID: 22811448
[TBL] [Abstract][Full Text] [Related]
6. Bayesian interim analysis of phase II cancer clinical trials.
Heitjan DF
Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
[TBL] [Abstract][Full Text] [Related]
7. Bayesian designs with frequentist and Bayesian error rate considerations.
Wang YG; Leung DH; Li M; Tan SB
Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
9. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
10. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
11. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
Berry SM; Broglio KR; Groshen S; Berry DA
Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
[TBL] [Abstract][Full Text] [Related]
12. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
13. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
14. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
16. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
Stallard N; Todd S; Ryan EG; Gates S
BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
[TBL] [Abstract][Full Text] [Related]
18. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
19. Bayesian two-stage designs for phase II clinical trials.
Tan SB; Machin D
Stat Med; 2002 Jul; 21(14):1991-2012. PubMed ID: 12111883
[TBL] [Abstract][Full Text] [Related]
20. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]